Standardizing methods for assessing omega-3 fatty acid biostatus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Harris, William S. | - |
dc.contributor.author | von, Schacky C. | - |
dc.contributor.author | Park, Yongsoon | - |
dc.date.accessioned | 2022-07-16T11:08:10Z | - |
dc.date.available | 2022-07-16T11:08:10Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2013-03 | - |
dc.identifier.issn | 68151 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/163336 | - |
dc.description.abstract | The Omega-3 Index is the sum of EPA+DHA in RBC membranes expressed as a percent of total fatty acids. Typical levels range from 3% to 9%, with a US average value of between 5%-6%. The Index is a marker of tissue EPA+DHA and therefore reflects an individual's EPA+DHA status. The Omega-3 Index fulfills most of the criteria for a valid biomarker. In routine clinical practice, the Omega-3 Index can be used to assess baseline n-3 fatty acid status and to check for compliance with a recommendation to increase the n-3 fatty acid intake. In the research setting, the Omega-3 Index can likewise document compliance, both to confirm that those assigned to the n-3 fatty acid group followed instructions and that those assigned to placebo did not take n-3 fatty acid off protocol. In addition, the Omega-3 Index can be used as an inclusion criterion in trial design to confirm that only individuals most likely to benefit from n-3 fatty acid treatment are included. The widespread clinical implementation of the Omega-3 Index will allow clinicians to detect n-3 insufficiency, to better stratify patients with respect to risk for disease, and it could ultimately contribute to a reduced burden of chronic disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Nova Science Publishers, Inc. | - |
dc.title | Standardizing methods for assessing omega-3 fatty acid biostatus | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yongsoon | - |
dc.identifier.scopusid | 2-s2.0-84885020903 | - |
dc.identifier.bibliographicCitation | The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention, pp.385 - 398 | - |
dc.relation.isPartOf | The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention | - |
dc.citation.title | The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention | - |
dc.citation.startPage | 385 | - |
dc.citation.endPage | 398 | - |
dc.type.rims | ART | - |
dc.type.docType | Book Chapter | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.